StockNews.AISignal intelligence
Company intelligence

CNC

Centene Corporation · NYSE · Healthcare

Price$69.38+4.46% · +$2.96
Market cap34.27BEquity value
P / E27.5Trailing ratio
Volume4.08MLatest session
Market data

CNC price chart

TradingView
Related signals
1 min delayed

Browse public CNC signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CNCAug 17, 2026-3.14% since signal

Centene names CFO successor as Asher prepares retirement, signaling 2027 transition

Centene announced CFO Drew Asher will step down in December 2026 and retire by year-end 2027, with Chris Neczypor named as his successor effective January 1, 2027. Neczypor brings Lincoln Financial CFO experience and will work with Asher through 2027 to ensure a smooth transition. The company reaffirmed 2026 adjusted diluted EPS guidance above $4.80 amid ongoing transformation.

View signal analysis
CNCJul 28, 2026-3.50% since signal

Centene posts better Q2, raises 2026 outlook, signaling margin resilience

Centene beat Q2 estimates and raised its 2026 outlook, signaling margin resilience and earnings visibility. The improved guidance suggests ongoing cost discipline and favorable member mix, potentially supporting valuation if execution sustains through 2026. Near-term price action will hinge on CNC's ability to continue profitable growth amid policy and market dynamics.

View signal analysis
CNCJul 28, 2026-1.19% since signal

Centene raises 2026 outlook on profitability and margin improvements

Centene posted Q2 2026 results with GAAP EPS of $2.19 and adjusted $2.51, and raised its 2026 guidance. Revenue reached $53.6B, up 4% year over year, supported by PDP/Marketplace pricing and Medicaid trends. Improving health-benefits ratios, lower SG&A, strong cash flow, and debt paydown underpin the higher outlook and potential multiple re-rating for CNC.

View signal analysis
CNCJul 28, 2026-1.19% since signal

Centene lifts 2026 guidance on stronger profitability and revenue mix

Centene headquarters earnings for Q2 2026 were solid, with GAAP EPS of $2.19 and adjusted EPS of $2.51, accompanied by a raised full-year outlook (GAAP >$3.11, adjusted >$4.80). Profitability improvements across Commercial, Medicare, and Medicaid boosted Health Benefits Ratios and lowered SG&A, while cash flow strengthened and debt was reduced via note repurchases. The upgrade reflects the company’s path to profitability and could support multiple expansion in CNC shares over the near term.

View signal analysis
CNCJun 15, 2026-3.19% since signal

Centene weighs voluntary buyouts amid ACA declines and Medicaid cuts loom

Centene announced a voluntary separation program as it confronts rising medical costs, funding cuts, and a shrinking membership base. First-quarter membership dropped 6% to 26.3 million, with ACA members down 2 million; management now expects ACA membership to fall nearly 40% by 2026. The company also flags more than $900 billion in Medicaid cuts over the next decade, pressuring margins and driving potential further cost-reduction actions.

View signal analysis
Research

Company intelligence